BACKGROUND: Patients with end-stage-liver-disease (ESLD) require orthotopic liver transplantation (OLT) as treatment. However, cirrhotic cardiomyopathy can be clinically revealed during OLT, with the possible development of a transient overt congestive heart failure. A number of patients require a combined procedure of liver transplantation and heart surgery, which includes heart transplantation, aortic valve replacement or coronary artery bypass grafting. Indications for combined liver-heart transplantation include heart failure with associated cardiac cirrhosis, familial amyloidosis, familial hypercholesterolemia and hemochromatosis, and homozygous β-thalassemia. METHODS/RESULTS. We performed a thorough research of Pubmed/ Medline, gathering and discussing data concerning this clinical condition and its treatment. CONCLUSION: In patients with end-stage liver disease, who are unable to tolerate an OLT post-operatively due to cardiac dysfunction, combined cardiac surgery and OLT appears to have certain advantages.
BACKGROUND:Patients with end-stage-liver-disease (ESLD) require orthotopic liver transplantation (OLT) as treatment. However, cirrhotic cardiomyopathy can be clinically revealed during OLT, with the possible development of a transient overt congestive heart failure. A number of patients require a combined procedure of liver transplantation and heart surgery, which includes heart transplantation, aortic valve replacement or coronary artery bypass grafting. Indications for combined liver-heart transplantation include heart failure with associated cardiac cirrhosis, familial amyloidosis, familial hypercholesterolemia and hemochromatosis, and homozygous β-thalassemia. METHODS/RESULTS. We performed a thorough research of Pubmed/ Medline, gathering and discussing data concerning this clinical condition and its treatment. CONCLUSION: In patients with end-stage liver disease, who are unable to tolerate an OLT post-operatively due to cardiac dysfunction, combined cardiac surgery and OLT appears to have certain advantages.
Authors: Jonathan D Harrison; Craig H Selzman; Heather F Thiesset; Terry Box; William R Hutson; Jeffrey K Lu; Jeffrey Campsen; John B Sorensen; Robin D Kim Journal: Surg Today Date: 2013-04-16 Impact factor: 2.549
Authors: Edward Coverstone; Kevin Korenblat; Jeffrey S Crippin; William C Chapman; Andrew M Kates; Alan Zajarias Journal: Case Rep Cardiol Date: 2014-11-09
Authors: Andrea De Martino; Stefano Pratali; Paola Carrai; Stefania Petruccelli; Paolo De Simone; Uberto Bortolotti Journal: Gen Thorac Cardiovasc Surg Date: 2020-07-12